Daehan New Pharm Co. Ltd
Daehan Nupharm Co.,Ltd. manufactures and sells pharmaceuticals and veterinary products in South Korea and internationally. It offers pharmaceuticals drugs for cardiovascular, endocrine system, neuropsychiatric, gastrointestinal, respiratory system, antipyretic, analgesic, anti-inflammatory, anti-infective, musculoskeletal, osteoporosis, anti-cancer, urogenital system, antifungal, antiviral, hormo… Read more
Daehan New Pharm Co. Ltd (054670) - Total Liabilities
Latest total liabilities as of September 2025: ₩122.10 Billion KRW
Based on the latest financial reports, Daehan New Pharm Co. Ltd (054670) has total liabilities worth ₩122.10 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Daehan New Pharm Co. Ltd - Total Liabilities Trend (2014–2024)
This chart illustrates how Daehan New Pharm Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Daehan New Pharm Co. Ltd Competitors by Total Liabilities
The table below lists competitors of Daehan New Pharm Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Huneed Tech
KO:005870
|
Korea | ₩127.55 Billion |
|
Laxmi Goldorna House Ltd
NSE:LGHL
|
India | ₹1.19 Billion |
|
Man Zai Industrial Co Ltd
TWO:4543
|
Taiwan | NT$767.12 Million |
|
Neogrid Participações S.A
SA:NGRD3
|
Brazil | R$135.18 Million |
|
Shin Nippon Biomedical Laboratories, Ltd.
PINK:SBLOF
|
USA | $52.75 Billion |
|
Lumbee Guaranty Bank
OTCQX:LUMB
|
USA | $474.61 Million |
|
Pappajack Bhd
KLSE:0242
|
Malaysia | RM89.58 Million |
|
MIRA Pharmaceuticals, Inc. Common Stock
NASDAQ:MIRA
|
USA | $83.93K |
Liability Composition Analysis (2014–2024)
This chart breaks down Daehan New Pharm Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.61 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.94 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.49 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Daehan New Pharm Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Daehan New Pharm Co. Ltd (2014–2024)
The table below shows the annual total liabilities of Daehan New Pharm Co. Ltd from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩95.85 Billion | +41.84% |
| 2023-12-31 | ₩67.57 Billion | +1.76% |
| 2022-12-31 | ₩66.40 Billion | -11.68% |
| 2021-12-31 | ₩75.18 Billion | -1.01% |
| 2020-12-31 | ₩75.95 Billion | +13.62% |
| 2019-12-31 | ₩66.84 Billion | +1.80% |
| 2018-12-31 | ₩65.66 Billion | -6.33% |
| 2017-12-31 | ₩70.09 Billion | +17.77% |
| 2016-12-31 | ₩59.52 Billion | +7.38% |
| 2015-12-31 | ₩55.43 Billion | -2.03% |
| 2014-12-31 | ₩56.58 Billion | -- |